219 related articles for article (PubMed ID: 35936009)
1. Hemidesmosomal Reactivity and Treatment Recommendations in Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid-A Retrospective, Monocentric Study.
Schauer F; Rafei-Shamsabadi D; Mai S; Mai Y; Izumi K; Meiss F; Kiritsi D
Front Immunol; 2022; 13():953546. PubMed ID: 35936009
[TBL] [Abstract][Full Text] [Related]
2. Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors.
Said JT; Liu M; Talia J; Singer SB; Semenov YR; Wei EX; Mostaghimi A; Nelson CA; Giobbie-Hurder A; LeBoeuf NR
JAMA Dermatol; 2022 May; 158(5):552-557. PubMed ID: 35416925
[TBL] [Abstract][Full Text] [Related]
3. Basement membrane zone IgE deposition is associated with bullous pemphigoid disease severity and treatment results.
Kamata A; Kurihara Y; Funakoshi T; Takahashi H; Kuroda K; Hachiya T; Amagai M; Yamagami J
Br J Dermatol; 2020 May; 182(5):1221-1227. PubMed ID: 31330562
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint Inhibition May Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid.
Sadik CD; Langan EA; Grätz V; Zillikens D; Terheyden P
Front Immunol; 2019; 10():1934. PubMed ID: 31474998
[TBL] [Abstract][Full Text] [Related]
5. IgG, IgA and IgE autoantibodies against the ectodomain of BP180 in patients with bullous and cicatricial pemphigoid and linear IgA bullous dermatosis.
Christophoridis S; Büdinger L; Borradori L; Hunziker T; Merk HF; Hertl M
Br J Dermatol; 2000 Aug; 143(2):349-55. PubMed ID: 10951144
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.
Kawsar A; Edwards C; Patel P; Heywood RM; Gupta A; Mann J; Harland C; Heelan K; Larkin J; Lorigan P; Harwood CA; Matin RN; Fearfield L
Br J Dermatol; 2022 Dec; 187(6):981-987. PubMed ID: 35976170
[TBL] [Abstract][Full Text] [Related]
7. Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers.
Sadik CD; Langan EA; Gutzmer R; Fleischer MI; Loquai C; Reinhardt L; Meier F; Göppner D; Herbst RA; Zillikens D; Terheyden P
Front Immunol; 2020; 11():588582. PubMed ID: 33708189
[TBL] [Abstract][Full Text] [Related]
8. Bullous Pemphigoid With a Dual Pattern of Glomerular Immune Complex Disease.
Hoorn EJ; Taams NE; Hurskainen T; Salih M; Weening JJ; Jonkman MF; Pas HH; Schreurs MW
Am J Kidney Dis; 2016 Feb; 67(2):302-6. PubMed ID: 26616334
[TBL] [Abstract][Full Text] [Related]
9. Possible paraneoplastic syndrome case of bullous pemphigoid with immunoglobulin G anti-BP180 C-terminal domain antibodies associated with psoriasis and primary macroglobulinemia.
Maki N; Demitsu T; Umemoto N; Nagashima K; Nakamura T; Kakurai M; Nakamura S; Yamada T; Ishii N; Hashimoto T
J Dermatol; 2016 May; 43(5):571-4. PubMed ID: 26507447
[TBL] [Abstract][Full Text] [Related]
10. IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment.
Iwata H; Kamio N; Aoyama Y; Yamamoto Y; Hirako Y; Owaribe K; Kitajima Y
J Invest Dermatol; 2009 Apr; 129(4):919-26. PubMed ID: 19177144
[TBL] [Abstract][Full Text] [Related]
11. In vivo analysis of IgE autoantibodies in bullous pemphigoid: a study of 100 cases.
Moriuchi R; Nishie W; Ujiie H; Natsuga K; Shimizu H
J Dermatol Sci; 2015 Apr; 78(1):21-5. PubMed ID: 25724363
[TBL] [Abstract][Full Text] [Related]
12. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity.
van Beek N; Lüttmann N; Huebner F; Recke A; Karl I; Schulze FS; Zillikens D; Schmidt E
JAMA Dermatol; 2017 Jan; 153(1):30-38. PubMed ID: 27829102
[TBL] [Abstract][Full Text] [Related]
13. Patients with bullous pemphigoid and linear IgA disease show a dual IgA and IgG autoimmune response to BP180.
Kromminga A; Scheckenbach C; Georgi M; Hagel C; Arndt R; Christophers E; Bröcker EB; Zillikens D
J Autoimmun; 2000 Nov; 15(3):293-300. PubMed ID: 11040070
[TBL] [Abstract][Full Text] [Related]
14. Case Report: Bullous Pemphigoid Associated With Morphea and Lichen Sclerosus: Coincidental Diseases or Pathogenetic Association?
Maglie R; Baffa ME; Montefusco F; Pipitò C; Senatore S; Capassoni M; Maio V; Cerinic MM; Antiga E; Guiducci S
Front Immunol; 2022; 13():887279. PubMed ID: 35592319
[TBL] [Abstract][Full Text] [Related]
15. Bullous pemphigoid (BP) patients with selective IgG autoreactivity against BP230: Review of a rare but valuable cohort with impact on the comprehension of the pathogenesis of BP.
Ramcke T; Vicari E; Bolduan V; Enk A; Hadaschik E
J Dermatol Sci; 2022 Feb; 105(2):72-79. PubMed ID: 34930674
[TBL] [Abstract][Full Text] [Related]
16. [Bullous pemphigoid].
Schulze F; Kasperkiewicz M; Zillikens D; Schmidt E
Hautarzt; 2013 Dec; 64(12):931-43; quiz 944-5. PubMed ID: 24337308
[TBL] [Abstract][Full Text] [Related]
17. Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review.
Asdourian MS; Shah N; Jacoby TV; Reynolds KL; Chen ST
JAMA Dermatol; 2022 Aug; 158(8):933-941. PubMed ID: 35612829
[TBL] [Abstract][Full Text] [Related]
18. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
Mai Y; Nishie W; Izumi K; Shimizu H
Front Immunol; 2019; 10():1224. PubMed ID: 31191560
[TBL] [Abstract][Full Text] [Related]
19. [Programmed Death-1 Inhibitors-induced Bullous Pemphigoid in 21 Cases].
Li S; He C; Zuo Y; Jin H
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2020 Oct; 42(5):603-609. PubMed ID: 33131514
[TBL] [Abstract][Full Text] [Related]
20. Autoreactive Peripheral Blood T Helper Cell Responses in Bullous Pemphigoid and Elderly Patients With Pruritic Disorders.
Didona D; Scarsella L; Fehresti M; Solimani F; Juratli HA; Göbel M; Mühlenbein S; Holiangu L; Pieper J; Korff V; Schmidt T; Sitaru C; Eming R; Hertl M; Pollmann R
Front Immunol; 2021; 12():569287. PubMed ID: 33841390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
